The approval is based on data from a multicenter trial in which patients were randomized 2:1 to receive either 30 mcg of the sufentanil sublingual tablet as needed, or placebo, with treatment limited up to 48 hours following the procedure.
Sufentanil Sublingual Tablet (Dsuvia) Gets FDA Approval
Orginally Published At: Pain Management – Pharmacy […]
• Migraineurs demonstrate sensory over-responsiveness to everyday sensations• Sensory over-responsiveness is more common in migraineurs with aura (MWA)• Attack frequency correlates with sensory over-responsiveness and pain summation
Assessment of Responsiveness to Everyday Non-Noxious Stimuli in Pain-Free Migraineurs with vs Without Aura
Orginally Published At: Pain Journal
• In a 2016 survey of the United States population, 6% of children had chronic pain• Chronic pain was associated with greater odds of using emergency care in past year• Chronic pain was also associated with higher out-of-pocket medical expenses• Chronic pain was not associated with increased odds of using mental health services